Skip to main content
Bruno Medeiros, MD, Hematology, Stanford, CA

BrunoCarneiro DeMedeirosMD

Hematology Stanford, CA

Assistant Professor, Medicine - Hematology, Stanford University Medical Center

Are you Dr. Medeiros?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 54 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    300 Pasteur Dr
    Stanford, CA 94305
    Phone+1 650-723-4000
    Fax+1 650-724-5203

Summary

  • Dr. Bruno Medeiros, MD is a hematologist in Stanford, California. He is currently licensed to practice medicine in California and Colorado. He is affiliated with Stanford Health Care and is an Assistant Professor at Stanford University Medical Center.

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Hematology and Medical Oncology, 2002 - 2005
  • University of Colorado
    University of ColoradoResidency, Internal Medicine, 2000 - 2002
  • University of Connecticut
    University of ConnecticutInternship, Internal Medicine, 1999 - 2000
  • Federal University of Parana Faculty of Medicine
    Federal University of Parana Faculty of MedicineClass of 1998

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2006 - 2026
  • CO State Medical License
    CO State Medical License 2002 - 2005

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia
    Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid LeukemiaJune 14th, 2016